How to Trade Large-Impact Catalysts for Huge Stock Market Returns

Biotech stocks are paying out big-time this year, but it's not just because of COVID-19. Large-impact catalysts can cause a stock to surge double and triple digits in a single day. Today, analyst Sean McCloskey reveals how you can trade the fastest-moving catalysts for huge returns, week after week after week. Biotech stocks are paying out big-time this year, but it's not just because of COVID-19. Large-impact catalysts can cause a stock to surge double and triple digits in a single day. Today, analyst Sean McCloskey reveals how you can trade the fastest-moving catalysts for huge returns, week after week after week. [Energy and Capital logo] How to Trade Large-Impact Catalysts for Huge Stock Market Returns [Sean McCloskey Photo] By [Sean McCloskey]( Written Aug 27, 2021 Select healthcare and biotech stocks are paying out big-time this year, [and it’s not just because of COVID-19 and its many variants](. Take Trillium Therapeutics (NASDAQ: TRIL) for example. This struggling stock broke out and soared 187% after pharmaceutical giant Pfizer Inc. (NYSE: PFE) announced it will buy out the company for the hefty price tag of $2.6 billion. [Trillium 5 Day] Source: TradingView.com Andy Schmeltz, global president and general manager of Pfizer Oncology, notes in a press release confirming the acquisition: Today’s announcement reinforces our commitment to pursue scientific breakthroughs with the addition of potentially best-in-class molecules to our innovative pipeline. The proposed acquisition of Trillium builds on our strong track record of leadership in Oncology, enhancing our hematology portfolio as we strive to improve outcomes for people living with blood cancers around the globe. Our deep experience in understanding the science of blood cancers, along with the diverse knowledge base we have developed across our growing hematology portfolio of eight approved and investigational therapies, provide us with a foundation to advance these important potential medicines to patients who need them. Could This $6 Virginia Tech Upstart Be About to "Crucify" Coal? Approximately 153 U.S. coal plants are expected to shut down by 2025... Plants that currently power a staggering 9.7 million American homes. And now a bizarre metallic substance pioneered by [a tech operation scheming out of Reston, Virginia](... Could take over our crippled coal empire and snatch the $1.14 billion per year in revenues it will leave it its wake. Given that this tiny upstart’s making just over $1 million in revenues... What’s coming could spell a staggering 46,018% gain opportunity for those willing to act soon. What’s in [this breakthrough report]( reveals this may only be the beginning... [So click here now before this opportunity is gone.]( Timing Is Everything When Trading Biotech for Big Gains Traders who scored 187% gains on Trillium can chalk up their win to great timing. Since reaching all-time highs last December, the stock has been in a downtrend up until this week. Investors who bought at the top eight months ago may be sitting on a small gain at best. However, investors who added TRIL to their portfolio in the past few months — recognizing the fact that this stock was trading at a significant discount to its true value and a perfect buyout candidate — made a killing. More importantly, the timing of this trade revolved around a single catalyst — a buyout. If you take anything away from this article today, make sure it’s this. To successfully trade biotech, it’s all about timing your trade around the right catalyst. Now admittedly, it’s been a while since I personally have focused on biotech stocks, but let’s look at another example my followers capitalized on a few years back when I was still knee-deep in the sector. On April 5, 2018, I recommended a lesser-known biotech formerly named Seattle Genetics, now named Seagen Inc. (NASDAQ: SGEN), at a price of $53.38. By the end of the year, the stock had nearly doubled in value after rising over $80 per share. Shareholders who took my advice scored a 60% gain in only eight months! [SGEN 2018 Gains] The catalyst back in 2018 was an FDA approval on Seagen's Adcetris therapy for the treatment of Hodgkin's lymphoma. More specifically, this therapy represented the first FDA-approved regimen for frontline treatment of Stage 3 and 4 Hodgkin's lymphoma in over 40 years. That’s an incredibly significant single-event catalyst. And almost every week there are catalysts like the ones mentioned above for us to profit from. Facebook Has Already Bet $50 Billion on ThisForget 5G — 2021’s Biggest Gains Will Be Here Mark Zuckerberg is no fool. So when he invests $50 billion in a brand-new technology, you'd better pay attention — especially when venture capitalists have also plowed $45 billion in it. Apple and Google have quietly added it to more than 1 billion smartphones. And this exclusive video reveals why this new tech breakthrough is about to revolutionize the computing world... and make a lot of people very rich. Early investors stand to make extraordinary gains of as much as 9,910%. But you have to hurry — this technology is about to go mainstream. [Click here now to get the inside story.]( Take for example my colleague and fellow analyst Keith Kohl’s latest trade on Cara Therapeutics Inc. (NASDAQ: CARA). Keith identified a large-impact catalyst that was set to trigger on August 23, 2021. Cara Therapeutics’ New Drug Application for its Korsuva injection was set for an FDA decision with a strong likelihood of approval (and a surge in the stock price), so Keith issued a buy alert on Cara on August 16. Following the large-impact catalyst he had anticipated, shares of Cara popped, offering followers of Keith's [Topline Trader service]( the potential to lock in flash one-week gains as high as 45% before shares fell back down to Earth while investors took profits. As I said before, timing is everything. But with the right guidance and insights into the hundreds of catalysts out there during any given week, you could score a gain like this almost every week of the trading year. It’s simply one of the best ways to build your wealth with stocks and in relatively no time at all compared with other stocks and investment vehicles. Catalyst Trading in Biotech Could Offer Incredible Returns On any given day, the biotech sector has the potential to hand out the biggest, fastest gains of any sector. In fact, almost every day, one of the market's biggest winners will be an obscure biotech no one has ever heard of. This Monday it was Trillium. On Thursday it was Ascendis Pharma (NASDAQ: ASND), which soared 23% in early trading thanks to another large-impact catalyst. On Friday I'm sure we'll see another biotech pop for huge returns. Of course, timing is everything when trading around these large-impact catalysts, and you have to get in before the mainstream gets wind of them. The good news is I can virtually guarantee that [next week another little-known biotech could soar for huge gains]( as well. That’s why catalyst trading is so great for investors. It offers fast-moving trades with incredible upside that you can take advantage of almost every week — week after week and year after year. To your wealth, Sean McCloskey Editor, Energy and Capital [[follow basic]@TheRL_McCloskey on Twitter]( --------------------------------------------------------------- This Zero-Emission Fuel Will Lead the Next Energy Revolution Whether you believe in climate change or not, there will be a shift in discovering new and reliable energy. You see, the forest fires spreading on both the west AND east coasts are disrupting our energy supply. In fact, the source of 23% of America’s energy is dying. By the end of 2021, coal energy capacity will expire in 1.05 million homes. And if nothing’s done to halt this crisis, 67.8 million Americans could ultimately be left without power. Remember the deadly Texas power outage in February 2021? That only affected 5 million Americans. Think about the damage the loss of coal energy will cause. It’s such an important issue that finding a solution to our energy crisis is something both President Biden and former President Trump agree on. Fortunately, that solution might finally be within arm’s reach. There’s been a breakthrough in quantum technology that could lead us into a renewable energy revolution. I’m calling it “TriFuel-238.” A rod of this fuel no bigger than 35 nickels can power your home for up to 15 years. It’s 40,835 times more powerful and 67,389 times more potent than gasoline. Not to mention it’s 49.6% cheaper than coal and 17.9% cheaper than natural gas! But you must act quickly and get in on the ground floor of this power play. You could be one of the early investors pocketing a windfall of as much as 46,018%. [Click here now to get all the details.]( Browse Our Archives [Bezos Is Obsessed With THIS Tech]( [3 Red-Hot Sectors]( [Sneak a Peek at Apple’s Secret Research Unit]( [Two Kids in Dallas Earn $32,000 a Month Mining Crypto — Here's How You Could Do the Same]( [The Only Mining Stocks That Matter]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Energy and Capital, please add newsletter@energyandcapital.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Energy and Capital](, Copyright © 2021, [Angel Publishing LLC](. All rights reserved. 3 E Read Street, Baltimore, MD 21202. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Energy and Capital as well as a link to www.energyandcapital.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. Please read our [Privacy Policy](. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. [Energy and Capital]( does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors and consultants of Angel Publishing may actively trade in the investments discussed in this publication. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question.